Molecular Partners Plans to Enter Eye-Drug Market, CEO Says

Lock
This article is for subscribers only.

Molecular Partners AG, a Swiss biotechnology company holding an initial public offering this week, plans to challenge Roche Holding AG and Novartis AG in the $6 billion eye-drug market with an experimental treatment.

The drug, Abicipar, may be easier to use than existing medications such as Lucentis, marketed by Novartis and Roche, and Regeneron Pharmaceuticals Inc.’s Eylea, CEO Christian Zahnd said in an phone interview last week.